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A randomised trial comparing combination chemotherapy using mitomycin
C, mitozantrone and methotrexate (3M) with vincristine, anthracycine
and cyclophosphamide (VAC) in advanced breast cancer
T.J. Powles, A.L. Jones, I.R. Judson, J.R. Hardy & S.E. Ashley
Medical Breast Unit, Royal Marsden Hospital, Downs Road, Sutton, Surrey, UK.
Summary This paper describes a randomised clinical trial in patients with advanced breast cancer, comparing
the regimen 3M, mitomycin C 7-8 mg m 2 (day 1), mitozantrone 7-8 mg m-2 (day I and 21), methotrexate
35 mg m-2 (day 1 and 21) given on a 42 day cycle with a standard anthracycline containing regimen, VAC,
vincristine 1.4 mg m-2 (day 1), anthracycline (adriamycin or epirubicin) 30mg m-2 (day 1), cyclophosphamide
400 mg m-2 (day 1) given on a 21 day cycle. Of a total of 217 patients, 107 were randomised to 3M and 110
to VAC and a mean of 5.5 courses was given per patient. The overall response rate (complete and partial) was
53% (95% Confidence Limits (CL); 43-62%) for 3M and 49% (CL; 39-58%) for VAC. The response
according to sites of metastases was the same for both treatment groups. Symptomatic toxicity including
alopecia, neuropathy, vomiting (P<0.001) and nausea (P<0.01) were significantly less for 3M. Myelosup-
pression including leucopenia (P<0.001) and thrombocytopenia (P<0.001) was significantly greater with 3M
at day 21, although there was no difference in nadir counts in patients at special risk of myelosuppression and
there was no evidence of an increase in infective or bleeding complications. There was no significant difference
in the duration of response to 3M (10 months, CL 6-15) and VAC (11 months, CL 7-12), nor in survival
(3M, 8 months, CL 6-12; VAC, 10 months, CL 8-12). These results indicate that 3M is as effective as, but
has significantly less symptomatic toxicity than, an anthracycline containing regimen for the treatment of
advanced breast cancer.
Patients with locally advanced or metastatic breast cancer
who have failed endocrine treatment, or who have rapidly
progressive disease, may be eligible for chemotherapy.
Although combination chemotherapy using three or more
cytotoxic drugs achieves objectives response rats of 50-60%
(Canellos et al., 1976; Hoogstraten et al., 1976) there is little
or no long term survival advantage using the drugs currently
available (Canellos et al., 1976; Carbone et al., 1977; Powles
et al., 1980). Even with high dose chemotherapy the lack of
substantial survival advantage makes the increased treatment
related morbidity and mortality unacceptable (Rosner et al.,
1987; Jones et al., 1987; Eder et al., 1986). It is possible that
aggressive chemotherapy for subsets of patients, perhaps
younger patients with rapidly developing visceral disease,
may have some survival benefit.
However, the main objective in the treatment of advanced
breast cancer should be delay or palliation of disease related
symptoms. This depends on sufficient dosage of drugs to
achieve an objective response in most patients balanced
against the toxicity related to treatment (Tannock et al.,
1988). The commonly used combination of vincristine, adria-
mycin and cyclophosphamide (VAC), using somewhat higher
doses than we generally use, has been reported to give a 60%
objective response rate in advanced breast cancer (Rainey et
al., 1979) but with significant toxicity.
The alkylating agent mitomycin C and the anti-metabolite
methotrexate both have single agent activity in breast cancer
with low subjective toxicity (De Lena et al., 1982; van
Oosterom et al., 1982; Carter, 1976). However, when used in
combination with melphalan (Perez et al., 1984) cumulative
myelosuppression became a problem. Mitoxantrone (Novant-
rone [R] Lederle) is an anthracenedione which has equivalent
activity to doxorubicin in advanced breast cancer, but with a
lower incidence of nausea, vomiting and alopecia and also
less cardiac toxicity (Cornbleet et al., 1984; Neidhart et al.,
1983; Mouridsen et al., 1983). We have developed a com-
bination regimen 3M, comprising mitoxantrone, mitomycin
C and methotrexate. In a pilot study this regimen gave a
response rate of 60% with low objective toxicity (Powles et
al., 1987). We have now evaluated the 3M regimen against
the anthracycline containing regimen VAC (vincristine,
anthracycline (adriamycin or epirubicin) and cyclophospha-
mide) in a prospective randomised trial in patients with
advanced breast cancer.
Patients and methods
Patients
Between March 1985 and November 1989, 217 patients with
histologically confirmed breast cancer under the care of the
Medical Breast Unit at the Royal Marsden Hospital, Sutton
for whom cytotoxic chemotherapy was indicated, were con-
sidered eligible for this study. The study had been approved
by the hospital Ethics Committee and all patients gave in-
formed consent. Patients required assessable metastatic and/
or locally advanced breast cancer according to UICC criteria
and a life expectancy of at least 6 weeks. Patients were
ineligible if they had received prior chemotherapy either as
adjuvant treatment or for advanced disease. Prior to the start
of chemotherapy an interval was required of at least 3 weeks
after local radiotherapy and of 6 weeks since endocrine
therapy. Patients with significant non-metastatic cardiac,
renal or hepatic dysfunction were excluded from the study.
Although randomisation was not stratified the two groups
were well matched for age, menopausal status and prior
treatment. The distribution of sites of metastatic disease was
similar for the two groups. Details of patient characteristics
are given in Table 1.
A total of 217 patients were entered into the study and
after exclusions because of protocol violation (prior chemo-
therapy) there remained 106 patients who received 3M and
105 patients who received VAC. The median age was 55
(range 36-77) years for 3M and 58 (range 30-76) years for
VAC. The median disease-free interval (primary diagnosis to
first relapse) was similar for 3M (16 months) and VAC (15
months) and the median time from relapse to start of chemo-
therapy was also similar (8 months) for both regimens. Most
patients (66% for both 3M and VAC) had received prior
endocrine therapy consistent with our policy of using endo-
crine treatment for first relapse.
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Table I Characteristics ofpatients
No of patients
Exclusions because of previous
chemotherapy
Included in analysis
Median age (yr)
(range)
Menopausal status
pre
post
peri
unknown
Previous treatment
Adjuvant endocrine
chemotherapy
Endocrine for advanced disease
(responders)
Sites of disease
local
skin
nodal
lung
liver
bone
CNS
other
Interval from diagnosis to 1st relapse
(yr) median
(range)
Interval from 1st relapse to (mths) start
of chemo median
(range)
3M
107
1
106
55
(36-77)
15
83
4
3
23
0
71
(27)
47
9
41
35
31
59
5
32
16
VAC
110
S
105
58
(30-76)
15
80
S
4
26
0
73
(32)
50
10
24
40
34
63
1
39
15
(0-15) (0- 16)
8 months 8 months
0-15 yr 0-8 yr
Treatment
Patients randomised to 3M received mitomycin C 8 mgm-2,
i.v. every 6 weeks, mitozantrone 8 mg m2, i.v. and metho-
trexate 35 mg mr2 (maximum dose 50 mg), i.v. every 3 weeks.
This means that courses of mitomycin C, mitozantrone and
methotrexate (3M) alternated with courses of mitozantrone
and methotrexate (2M) every 3 weeks. All patients received
oral folinic acid 15 mg every 4 h for six doses starting 24 h
after methotrexate. These doses were rounded down to the
nearest milligram for administration and modified if there
was significant renal or hepatic dysfunction, if bone marrow
function was compromised by radiation, and according to
subsequent toxicity. Patients receiving VAC were given vin-
cristine 1.4 mg m-2 (maximum dose 2 mg), anthracycline
(either adriamycin or epirubicin) 30 mg m-2 and cyclophos-
phamide 400 mgm2 every 21 days. Treatment was usually
given on an out-patient basis. The choice of adriamycin or
epirubicin was made in a double-blind randomisation and as
previous studies had demonstrated there is no significant
difference in response rate, toxicity or survival between
epirubicin and adriamycin in combination regimens (French
Epirubicin Study Group, 1988). The doses of anthracycline,
cyclophosphamide, mitozantrone and mitomycin C were
modified if the white cell count (WBC) was less than
3.0 x I0 1' and/or platelet count less than 100 x 1091-'
(Table II) to avoid deferring treatment.
All patients received antiemetic prophylaxis with intra-
venous dexamethasone 8 mg and metoclopramide 20 mg
before each chemotherapy injection. Oral dexamethasone
(4 mg) and metoclopramide (10 mg) were generally given for
about 48 h after chemotherapy, subsequently modified
according to need. Patients receiving VAC were all offered
scalp cooling with chemotherapy provided they had adequate
liver function.
Patients who achieved an objective response or who had
stable disease with symptomatic relief continued to at least
six courses.
Assessment of response and toxicity
Patients were admitted to the assessment unit for full metas-
tatic staging (Coombes et al., 1980) and randomisation prior
Table II Dose modification according to day 21 counts
WBC x 1091-' Platelets x 1091-'
<3.0:> 2.0 < 100:> 75 75% standard dose
<2.0:> 1.0 <75:> 50 50% standard dose
<1.0: <50 No treatment (defer 1 week)
to the first course of chemotherapy. All visible lesions were
photographed, and specific investigations to document
tumour sites including chest X-ray, limited skeletal survey,
liver ultrasound and CT scan (if appropriate) were per-
formed. Whilst on treatment all patients were clinically
assessed in out-patients before each course of chemotherapy
together with a peripheral full blood count. Serum bio-
chemistry, appropriate X-rays and other scans used in assess-
ment were usually repeated after three cycles. Nadir counts
(day 10- 14) were obtained in those patients at particular risk
of myelosuppression (e.g. prior radiotherapy). Patients were
readmitted to the assessment unit in order to document
response according to UICC criteria (Hayward et al., 1977)
after six courses of chemotherapy, or earlier if they had signs
of progressive disease. Patients who died within 3 weeks of
starting treatment were not included in analysis of assessable
response but have been included in the overall response,
toxicity and survival results.
Toxicity
Non-haematological toxicity including alopecia, stomatitis
and neuropathy was defined according to WHO grading.
Because all patients in this trial received prophylactic anti-
emetics, and WHO criteria for nausea and vomiting were not
applicable. We therefore defined a different scoring system as
follows: Nausea: grade 1 - mild, still able to eat; grade 2 -
moderate, anoretic <24 h; grade 3 - severe anoretic >24 h.
Vomiting: grade 1 - mild, occasional vomits < 12 h; grade 2
- moderate, several vomits but <24 h; grade 3 - vomiting
>24 h. The severity of nausea and vomiting was assessed for
all courses.
Haematological toxicity was assessed according to WHO
criteria.
Statistical analysis
The chi-squared test and Mann-Whitney test for trend were
used to assess differences in patient characteristics, response
and toxicity. Survival analysis and duration of response from
randomisation was done by the Kaplan-Meier life table
method (Kaplan & Meier, 1958) and the log rank test (Peto
et al., 1977).
Results
Response
The response data are summarised in Table III. Of 211
patients randomised, 189 patients were assessable for re-
sponse. The remaining 10% of patients were inassessable for
response because of early deaths or inadequate follow-up.
There was no significant difference in the overall response
rate for 3M, 53% (95% CL 43-62%) and VAC 49% (95%
CL 39-58%). Six patients in each arm achieved a complete
remission. There was no difference in the assessable response
rate for 3M (60%; 95% CL 50-70%) and VAC (54%; 95%
CL 44-64%). The response rate by metastatic site was
similar for both arms.
The response duration is shown in Figure 1. There was no
significant difference in the median duration of response
which was 10 months (95% CL 6-15 months) for 3M and 11
months (95% CL 7-12 months) for VAC. Similarly there
was no difference in survival from the start of treatment
(Figure 2) which was 8 months (95% CL 6-12 months) for
3M and 10 months (95% CL 8-12 months) for VAC.408 T.J. POWLES et al.
Table III Response to 3M and VAC
3M VAC
Patients 106 105
No. assessable for response 94 95
Complete response 6 6
Partial response 50 45
No change 15 22
Progressive disease 23 22
Overall response (95% CL) 53 (43-62) 49 (39-58)
Assessable response (95% CL) 60 (50-70) 54 (44-64)
% Assessable response by site (95% CL)
local 50 (35-66) 52 (38-67)
skin 83 (54-100) 44 (12-77)
nodal 64 (49-79) 59 (35-54)
lung 38 (20-56) 37 (21-57)
liver 41 (22-59) 45 (27-63)
bone 36 (22-51) 51 (37-65)
a)
C
0
U) n 0)
CL
C.)
0)
._
0
c
0
co
iv
Time since start of treatment (years)
Figure 1 Duration of response after VAC (51 patients)
and 3M (56 patients) ----- (P>0.1).
1 2
Time since start of treatment (years)
1
Co
L-
0-
%.0
0
-0
0
Figure 2 Overall survival after VAC (105) patients and
3M (106 patients) ---- (P>0.1).
The average actual drug doses given for the total 603
courses of 3M are summarised in Table IV. The average
dosage of all three drugs was marginally less than the speci-
fied dosage reflecting only modest dose modification for
toxicity. The doses of all three drugs for all patients was the
same as for responding patients. The doses of mitozantrone
and methotrexate were significantly higher in the first 3M
and 2M courses than in later courses. The reduction in dose
of mitozantrone below 7 mg m-2 reflects a decrease in dose
on subsequent courses for patients who had evidence of
myelosuppression. Although the prescribed dose of metho-
trexate was 35 mg m2, the ceiling dose was 50 mg per course
therefore the actual dose given was <30mgm2.
The average doses of drugs for patients receiving VAC
were vincristine 1.26 mg m-2, anthracycline 27.6 mg m 2 and
Mg M-2 cyclophosphamide 415
Table IV Average drug dosages for 3M (mg m-2)
No of Mitomycin Mitozan- Metho-
courses C trone trexate
All courses
All patients 603 6.50 6.90 28.6
All 3M courses 342 6.50 7.20 28.9
All 2M courses 261 - 6.61 28.2
Assessable patients 572 6.51 6.92 28.6
Responding patients 414 6.55 6.90 28.5
First 3M and 2M courses
All patients 210 6.76 7.69 29.7
Assessable patients 194 6.85 7.66 29.8
Responding patients 115 6.97 7.70 30.1
Toxicity
Non-haematological toxicity for patients receiving 3M was
low (Table V) and the main differences were the lack of
significant neuropathy (P<0.001) and the reduction in alo-
pecia (P<0.001). Fifty-four per cent of patients receiving
VAC had alopecia >,grade 2, despite scalp cooling, com-
pared with only 7% of patients receiving 3M. There was no
difference in stomatitis between the two arms. Nausea and
vomiting were analysed separately by individual courses
using the toxicity grading system described above. Nausea
(P<0.01) and vomiting (P<0.001) were significantly less
for 3M compared with VAC.
The data for haematological toxicity measured at day 21
(i.e. the time of next treatment) are presented in Table VI.
The trend for myelosuppression was greater with 3M than
VAC for all parameters (P<0.001) although the actual
number of courses with grade 3/4 myelosuppression was low.
In 90 patients who had nadir counts (day 10-14) because
they were considered at special risk of myelosuppression (e.g.
because of previous radiotherapy), there was no significant
difference in myelosuppression (Table VII). Systemic infec-
tion requiring parenteral antibiotics related to myelosuppres-
sion occurred in two patients receiving 3M and in five
patients receiving VAC. There were no treatment related
deaths.
Differences in myelosuppression after courses of 3M (with
mitomycin C) and 2M (without mitomycin C) were com-
pared by peripheral blood counts on days 21 (Table VIII).
There was significantly greater grade 3 and 4 leucopenia
(P = <0.005) and thrombocytopenia (P = <0.01) following
3M than 2M courses.
Discussion
In this study of the use of first-line chemotherapy for meta-
static breast cancer, the combination of mitomycin C, mito-
zantrone and methotrexate (3M) is as safe and effective as
VAC but has significantly less subjective toxicity. There was
no significant difference in the objective response rate, dura-
tion of remission or survival when 3M was compared to
VAC and the response rate was similar to that reported for
other non-intensive combinations (Canellos et al., 1976;
Hoogstraten et al., 1976; Rainey et al., 1979; Cummings et
al., 1985). All patients had advanced local or metastatic
disease at the time of starting chemotherapy and most had
previously received endocrine therapy for relapse. Hence
chemotherapy was given late in the natural history of meta-
static breast cancer and this is reflected by the relatively short
survival from the start oftreatment (8 months for 3M and 10
months for VAC). In addition patients were not excluded on
the basis of adverse survival features such as rapidly progres-
sive disease, poor performance status or visceral disease.
Comparisons of the survival data in this programme with
that reported in other programmes when chemotherapy is
used at first relapse or for minimal disease is therefore not
valid.
Although general health dimensions were not assessed by
quality of life assessments (Coates et al., 1987; Tannock et
U
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Table V Non haematological toxicity: number of patients (%) experiencing alopecia,
neuropathy and stomatitis; number of courses (%) associated with nausea and
vomiting
3M VAC
WHO grade: 0 1 2 3/4 0 1 2 3/4
Alopecia 64 28 5 2 26 13 17 29
(65) (28) (5) (2) (31) (15) (20) (34) (P<0.001)
Neuopathy 95 3 1 49 20 12 4
(95) (3) (1) (58) (24) (14) (5) (P<0.001)
Stomatitis 70 18 9 1 63 12 9 1
(70) (18) (9) (1) (74) (14) (11) (1) (NS)
Toxicity grade: 0 1 2 3/4 0 1 2 3/4
Nausea 470 97 52 8 326 104 43 10
(75) (15) (8) (1) (67) (22) (9) (2) (P<0.01)
Vomiting 558 39 25 4 393 61 22 8
(89) (6) (4) (1) (81) (13) (5) (2) (P<0.001)
Table VI Haematological toxicity expressed as number (%) ofcourses complicated by
indicated toxicity as measured at the time ofnext treatment (i.e. Day 21) in 110 patients
receiving VAC vs 107 patients receiving 3M
WHO Grade
Total 0 1 2 3/4
Anaemia >11.0 9.5-10.9 8.0-9.4 <7.9 g dl
3M 519 371 (71) 120 (23) 24 (5) 4 (1) (P<0.001)
VAC 429 350 (82) 61 (14) 16 (4) 2 (1)
Leucopenia >4.0 3.0-3.9 2.0-2.9 41.9x 1091-1
3M 519 322 (62) 114 (22) 68 (13) 15 (3) (P<0.001)
VAC 429 333 (77) 68 (16) 27 (6) 1 (1)
Thrombocytopenia >100 75-99 50-74 <50 x 1091-'
3M 519 495 (95) 8 (2) 9 (2) 7 (1) (P<0.001)
VAC 429 427 (99) 1 (<1) 1 (<1) 0 (0)
Table VII Haematological toxicity expressed as number (%) ofcourses complicated by
theindicated toxicity measured at nadircount(day 10-14) in 90patients atspecial risk of
myelosuppression
WHO Grade
Total 0 1 2 3/4
Anaemia >11.0 9.5-10.9 8.0-9.4 <7.9gdl-
3M 58 26 (45) 16 (28) 13 (22) 3 (5) NS
VAC 59 34 14 11 0
Leucopenia >4.0 3.0-3.9 2.0-2.9 41.9x 1091-l
3M 58 8 (14) 8 (14) 16 (28) 26 (45) NS
VAC 59 15 (25) 6 (10) 13 (22) 25 (42)
Thrombocytopenia >100 75-99 50-74 <50 x 1091-1
3M 58 50 (86) 1 (2) 4 (7) 3 (5) NS
VAC 59 53 (90) 1 (2) 4 (7) 1 (2)
Table VIII Number (%) ofalternative courses ofthree drugs (3M) and two drugs (2M)
complicated by the indicated haematological toxicity (day 21)
WHO Grade
Total 0 1 2 3/4
Anaemia
3M 318 212 68 (21) 31 (10) 7 (2)
2M 219 153 55 (25) 10 (5) 1 (<1) (NS)
Leucopenia
3M 318 177 58 (18) 43 (14) 40 (12)*
2M 219 135 40 (18) 33 (15) 11 (5) (P<0.005)
Thrombocytopenia
3M 318 293 5 (2) 9 (3) 11 (4)**
2M 219 211 4 (2) 4 (2) 0 (P<0.01)
*P<0.005; **P<0.01.
al., 1988) the major treatment related toxicities, nausea,
vomiting and alopecia were significantly less with 3M than
VAC. We did not observe any pulmonary, renal, hepatic or
cardiac toxicity, presumably because the bolus and cumula-
tive doses for each drug were low. There was no significant
differences between 3M and VAC for haematological toxicity
assessed by nadir counts and the increase in grade 3 and 4
haematological toxicity for 3M at day 21 was not associated
with any excess in clinical complications. It would appear
from comparison of 3M and 2M courses that mitomycin C
did contribute to overall myelotoxicity assessed by grade 3/4
leucopenia and thrombocytopenia. Comparison of drug
dosages for 3M in responding and non-responding patients
indicates that higher dosages of these drugs would not neces-
sarily increase the response rate and might be associated with
an increase in haematological toxicity.
In conclusion, this study indicates that this 3M combina-
tion of mitomycin C, mitozantrone and methotrexate is an
effective regimen, with low subjective toxicity, for use as
first-line chemotherapy in advanced breast cancer. Further
comparison, including formal quality of life measurements
with other standard regimens will give further indication of
its palliative efficacy. The safety and low toxicity profile
make 3M a possible chemotherapy option for clinical trials
of adjuvant treatment or primary medical treatment of breast
cancer.410 T.J. POWLES et al.
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